SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 104 500 KRW -0.19%
Market Cap: 8.2T KRW
Have any thoughts about
SK Biopharmaceuticals Co Ltd?
Write Note

SK Biopharmaceuticals Co Ltd
Other Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SK Biopharmaceuticals Co Ltd
Other Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Assets CAGR 3Y CAGR 5Y CAGR 10Y
SK Biopharmaceuticals Co Ltd
KRX:326030
Other Assets
â‚©3.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Other Assets
â‚©123.9B
CAGR 3-Years
896%
CAGR 5-Years
100%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Other Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Other Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Other Assets
â‚©3.7B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
C
Celltrion Pharm Inc
KOSDAQ:068760
Other Assets
â‚©32.9B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
No Stocks Found

SK Biopharmaceuticals Co Ltd
Glance View

Market Cap
8.2T KRW
Industry
Pharmaceuticals

SK Biopharmaceuticals Co., Ltd., a prominent player in the global biopharmaceutical industry, emerged as a distinctive entity out of one of South Korea's largest conglomerates, the SK Group. This pharmaceutical jewel draws its strength from innovation in the neurology and oncology sectors, fields brimming with both challenge and opportunity. At its core, SK Biopharmaceuticals is dedicated to the research, development, and commercialization of novel medications, with a significant focus on disorders impacting the central nervous system. Their pipeline and commercial activities revolve around cutting-edge therapies, such as the epilepsy drug Cenobamate, which has gained a foothold in both the U.S. and European markets. This drug, marketed under different names like Xcopri in the U.S., is a testament to the company's ability to leverage robust R&D capabilities into profitable products. Revenue generation for SK Biopharmaceuticals is predominantly driven by the sales of their innovative therapeutic solutions, as well as strategic collaborations with a network of global partners. They engage in a lifecycle approach where they not only develop and launch their own drugs but also license out their intellectual property, enhancing revenue streams through royalties and milestone payments. This hybrid model of sales and strategic partnerships showcases a deft mix of scientific prowess and commercial acumen, key to sustaining and propelling growth in a competitive market. Additionally, they continuously invest in research and alliances, aiming to expand their portfolio beyond existing successes, while targeting unmet medical needs that mirror their core strengths. This balanced approach positions SK Biopharmaceuticals not just as a standalone drugmaker, but as a dynamic player in shaping future therapies in their chosen niches.

Intrinsic Value
42 433.46 KRW
Overvaluation 59%
Intrinsic Value
Price

See Also

What is SK Biopharmaceuticals Co Ltd's Other Assets?
Other Assets
3.4B KRW

Based on the financial report for Dec 31, 2023, SK Biopharmaceuticals Co Ltd's Other Assets amounts to 3.4B KRW.

Back to Top